Wei, J.Q.; Yuile, A.; Itchins, M.; Kong, B.Y.; Li, B.T.; Pavlakis, N.; Chan, D.L.; Clarke, S.J.
Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis. Biomedicines 2023, 11, 1827.
https://doi.org/10.3390/biomedicines11071827
AMA Style
Wei JQ, Yuile A, Itchins M, Kong BY, Li BT, Pavlakis N, Chan DL, Clarke SJ.
Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis. Biomedicines. 2023; 11(7):1827.
https://doi.org/10.3390/biomedicines11071827
Chicago/Turabian Style
Wei, Joe Q., Alexander Yuile, Malinda Itchins, Benjamin Y. Kong, Bob T. Li, Nick Pavlakis, David L. Chan, and Stephen J. Clarke.
2023. "Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis" Biomedicines 11, no. 7: 1827.
https://doi.org/10.3390/biomedicines11071827
APA Style
Wei, J. Q., Yuile, A., Itchins, M., Kong, B. Y., Li, B. T., Pavlakis, N., Chan, D. L., & Clarke, S. J.
(2023). Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis. Biomedicines, 11(7), 1827.
https://doi.org/10.3390/biomedicines11071827